Ligacim Bio FY 2025 Annual ReportBeta
Ligacim Bio annual report for FY 2025, filed with DART (Korea Financial Supervisory Service) on March 23, 2026. This page provides AI-powered English analysis including business overview, management discussion & analysis (MD&A), risk factors, and KIFRS consolidated financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE).
Ligacim Bio FY 2025 Annual Report Analysis
Business Overview
- • ADC platform "ConjuALL" technology with multiple global licensing deals totaling approx. KRW 9.4T milestone secured in FY2025
- • FY2025 technology transfer revenue KRW 1.21T from ADC candidates and platform, up from KRW 1.05T in 2024
Management Discussion & Analysis
- • Revenue KRW 141.6B (+12.4% YoY), operating loss KRW 10.6B (-409%), net loss KRW 9.2B vs net income KRW 0.78B prior year
- • Technology licensing revenue KRW 121.2B (+15%) drove growth, attributed to patent-protected proprietary linker and payload technologies
Risk Factors
- • KRW 57.4B put option liability reclassified as equity deduction due to Iksuda Therapeutics Limited control acquisition in FY2025
- • FY2025 removal of KRW 17.0B derivative liability related to prior Iksuda Therapeutics Limited forward share contracts
Ligacim Bio FY 2025 Key Financial MetricsDART
Total Assets
KRW 701.8B
▼ -5.0% YoY
Operating Cash Flow
-KRW 124.5B
▼ -258.7% YoY
CapEx
KRW 3.0B
▲ +16.1% YoY
Source: KIFRS consolidated financial data from Ligacim Bio annual report on DART. All figures in KRW.
Source: DART (Korea Financial Supervisory Service) · AI summaries generated from the original Korean filing (English output) · Beta: coverage is expanding